Targets › NAMPT
8 programs from 8 companies in 14 trials: 8 Phase 2, 4 Phase 1, 1 Phase 4, 1 Phase 3; Other, Oncology, Neurology; next expected readout Dec 2026.
Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack…. (UniProt, P43490)
Open in Phaseline: the race on NAMPT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Oklahoma | Nicotinamide riboside NAD+ precursor; increases cellular NAD+ levels | NAMPT | Phase 4 | Aging | Jun 2027 |
| ORIC Pharmaceuticals | Rinzimetostat NAMPT inhibitor | NAMPT | Phase 3 | Metastatic Castration Resistant Prostate Cancer | Mar 2028 |
| University of Colorado, Denver | Nicotinamide Riboside NAD+ precursor, vitamin B3 derivative that replenishes intracellular NAD+ pools | NAMPT | Phase 2 | Vascular Diseases; Clonal Cytopenia of Undetermined Significance | Jul 2027 |
| Haukeland University Hospital | Nicotinamide Riboside (NR) NAD+ precursor; increases cellular NAD+ levels | NAMPT | Phase 2 | Sleep; Multiple Sclerosis; Frailty; Progressive Supranuclear Palsy … | Aug 2027 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Nicotinamide (NAM) NAD+ precursor; promotes NAD+ biosynthesis and may support cellular metabolism and anti-in | PARP1, NAD1, NAMPT | Phase 2 | Fatty Liver | Dec 2027 |
| Metro International Biotech | Nicotinamide Mononucleotide (NMN) NAD+ precursor; substrate for nicotinamide phosphoribosyltransferase (NAMPT) | NAMPT | Phase 1 | Healthy Adults | Dec 2026 |
| The University of Texas Health Science Center, Houston | Nicotinamide riboside (NR) NAD+ precursor; increases cellular NAD+ levels through the salvage pathway | NAMPT | Phase 1 | Smooth Muscle Dysfunction Syndrome (SMDS) | Jul 2027 |
| Remedy Plan | RPT1G Selective hyperbolic NAMPT inhibitor | NAMPT | Phase 1 | Acute Myeloid Leukemia | Dec 2028 |
Healthy Adults (2) Sleep (1) Multiple Sclerosis (1) Frailty (1) Progressive Supranuclear Palsy (1) Alzheimer Disease (AD) (1) Vascular Diseases (1) Clonal Cytopenia of Undetermined Significance (1) Aging (1) Metastatic Castration Resistant Prostate Cancer (1) Fatty Liver (1) Smooth Muscle Dysfunction Syndrome (SMDS) (1)
small molecule (6), mixed (1)
Haukeland University Hospital (1) University of Colorado, Denver (1) University of Oklahoma (1) ORIC Pharmaceuticals (1) Metro International Biotech (1) Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) The University of Texas Health Science Center, Houston (1) Remedy Plan (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.